Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01286168 · ClinicalTrials.gov registry record · Phase 2
Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction
A Phase 2 study of Breast Cancer and Nonmalignant Breast Conditions, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 2
- Study locations
NCT01286168: Completed Phase 2 study of Breast Cancer and Nonmalignant Breast Conditions, sponsored by Mayo Clinic.
NCT01286168 is a Phase 2 study of Breast Cancer and Nonmalignant Breast Conditions that has completed, run by Mayo Clinic. The registered enrollment target is 110 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01286168, a Phase 2 study of Breast Cancer and Nonmalignant Breast Conditions, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 2
- Study locations
Study Summary
Surgical site infection (SSI) after breast and axillary surgery occurs more often than for other clean surgical procedures. Infection in the setting of a tissue expander can be devastating and can lead to early implant loss and failed reconstruction. Surgical drains have been noted as a potential source for surgical site infections. Hypothesis: Bacteria present in surgical drains after tissue expander reconstruction may be decreased by simple and inexpensive local antiseptic interventions.
Primary Outcome
Bacterial growth was defined as plate growth of 1+ or greater. Drains were removed at variable times across patients, per clinical indication. When clinically indicated, some patients did have their drains removed at the one week visit, in which case they only had one bulb fluid culture.
Conditions Studied
Interventions
- PROCEDURE Control
- DEVICE Sodium hypochlorite (Dakin's Solution)
- DEVICE Chlorhexidine gluconate disk
- DEVICE Occlusive Adhesive Dressing
Study Locations (2)
California
- UCSF - San Francisco
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT01286168 record still lists
NCT01286168 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Control is the first listed.
NCT01286168 reports a single indexed study location in California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01286168 about?
NCT01286168 is a clinical study titled "Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction". Surgical site infection (SSI) after breast and axillary surgery occurs more often than for other clean surgical procedures. Infection in the setting of a tissue expander can be devastating and can lead to early implant loss and failed reconstruction. Surgical drains have been noted as a potential so...
What is the current status of trial NCT01286168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2011-05. Estimated completion is 2013-11.
What conditions does trial NCT01286168 study?
This clinical trial studies the following conditions: Breast Cancer, Nonmalignant Breast Conditions.
What interventions are being tested in trial NCT01286168?
The interventions under investigation include: Control (PROCEDURE), Sodium hypochlorite (Dakin's Solution) (DEVICE), Chlorhexidine gluconate disk (DEVICE), Occlusive Adhesive Dressing (DEVICE).
Who is sponsoring clinical trial NCT01286168?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01286168 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01286168's enrollment target sits among peer trials
110 536th of 1224 higher than 684 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- NCT03245411 · 110 participants · NA
Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia